北京市中伦（广州）律师事务所 关于广州迈普再生医学科技股份有限公司 2023 年第一次临时股东大会的 法律意见书 二〇二三年八月 广东省广州市天河区珠江新城华夏路 10 号富力中心 23 楼整层及 31 楼 01、04 单元 邮编：510623 23/F, Units 01 & 04 of 31/F, R&F Center, 10 Huaxia Road, Zhujiang New Town, Tianhe District Guangzhou, Guangdong 510623, P. R. China 电话/Tel : +86 20 2826 1688 传真/Fax : +86 20 2826 1666 www.zhonglun.com 北京市中伦（广州）律师事务所 关于广州迈普再生医学科技股份有限公司 2023 年第一次临时股东大会的法律意见书 致：广州迈普再生医学科技股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）接受广州迈普再生医 学科技股份有限公司（以下简称"公司"）委托，指派孙巧芬和曾思律师（以下 简称"本所律师"）对公司 2023 年第一次临时股东大会（以下简称"本次股东 大会" ...

股东大会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2023-034 广州迈普再生医学科技股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日下午 14:30 以现场表决和网络投票相结合的方式召开公 司 2023 年第一次临时股东大会。 1、会议召开时间：2023 年 8 月 17 日（星期四）下午 14:30； 2、会议召开地点：广州市黄埔区崖鹰石路 3 号迈普医学大厦会 议室。 3、会议召开方式：采取现场表决与网络投票相结合的方式。现 场会议召开时间：2023 年 8 月 17 日（星期四）下午 14:30。网络投 票时间：通过深圳证券交易所交易系统进行网络投票的时间为：2023 股东大会决议公告 年 8 月 17 日上午 9:15-9:25，9:3 ...

核查意见及公示情况说明 证券代码：301033 证券简称：迈普医学 公告编号：2023-033 广州迈普再生医学科技股份有限公司 监事会关于公司 2023 年限制性股票激励计划首次授予部分 激励对象名单的核查意见及公示情况说明 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2023 年 7 月 31 日召开第二届董事会第十六次会议、第二届监事会第十二 次会议，审议通过了《关于<广州迈普再生医学科技股份有限公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案，具 体 内 容 详 见 公 司 于 2023 年 8 月 1 日 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的相关公告。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管 理办法》（以下简称"《管理办法》"）、《深圳证券交易所创业板股票上 市规则》（以下简称"《上市规则》"）、《深圳证券交易所创业板上市公 司自律 ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2023007 ☑特定对象调研 ☐分析师会议 ☐媒体采访 投 资 者 关 系 活动类别 ☐业绩说明会 ☐新闻发布会 ☐路演活动 ☑现场参观 ☐一对一沟通 ☐其他： 广东上市公司协会：封志敏、赵思皓；华泰证券：唐佳、陈 参 与 单 位 名 称 及 人 员 姓 名 放、林晓宇、柯小凡、冯斯焕、蔺金秀；投资者：冯强、赵 翠华、张博、杨林成、张小玲、李苏霖、方婷、杨惠雄、欧 阳帅、吴桂玲、陈衍熹、王依钿、林穗婷、于玮、王煜。 时间 2023 年 7 月 5 日 15:00-17:30 地点 公司展厅及会议室 上 市 公 司 接 待人员 董事、董事会秘书：龙小燕 一、公司董事会秘书简单介绍公司基本情况 公司成立于 2008 年，于 2021 年 7 月 26 日在深交所创 业板上市，公司是一家专注于高性能植入医疗器械的科技创 新型企业，如今已经发展成为中国领先且进入全球高端市场 投 资 者 关 系 活 动 主 要 内 容介绍 的医疗器械公司之一。 公司以患者生命健康为根本、以临床需求为导向，在全 球率先实现生物增材 ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2023006 ☑特定对象调研 ☐分析师会议 ☐媒体采访 投 资 者 关 系 活动类别 ☐业绩说明会 ☐新闻发布会 ☐路演活动 ☑现场参观 ☐一对一沟通 ☐其他： 中信证券 宋硕、曾令鹏、朱晓、哈帅、陈乐雁;相聚资本 邓巧; 康曼德资本 耿浩；深圳景元天成 詹俊彦；Phillip 参 与 单 位 名 称 及 人 员 姓 名 王骊鹏；永赢基金 张蕊 ；Indus Capital 谭震；前海开源 黄智然；清池资本 金靓竹；广发自营 杨正；招商资管 徐 文；高毅资产 罗鸣；华安基金 杨磊；高正资本 李立卓； 广州利德曼 张绪帆；高新科控 刘美婷；湘财基金 张泉。 时间 2023 年 6 月 14 日 13:00-15:00 地点 公司展厅及会议室 董事、副总经理、财务总监：骆雅红 上 市 公 司 接 待人员 董事、董事会秘书：龙小燕 一、公司董事会秘书简单介绍公司基本情况 2022 年，公司实现营业收入 19,525.24 万元，同比增长 投 资 者 关 系 活 动 主 要 内 容介绍 26.96%，实现归属于 ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2023005 ☑特定对象调研 ☐分析师会议 ☐媒体采访 投 资 者 关 系 活动类别 ☐业绩说明会 ☐新闻发布会 ☐路演活动 ☑现场参观 ☐一对一沟通 ☐其他： 中信证券 李芳芳、陈禧琳、沈博爱；国健安基金 何卫国； 兴业证券 蔡佳文；汇垠澳丰 欧阳志雄；中财集团 董学 兵；东方财富证券 尹元彪；兰丞资本 罗小明；天运投资 梁海康；红猫资管 钟小兵；紫薇基金 刘畅；亚太汇 滕 参 与 单 位 名 称 及 人 员 姓 名 涛；华天联合产业基金 苏红军；东吴证券 黄毅、李林森； 祈福集团 谭德祺、李晓芬；渤海银行 卢镇；中山证券 邱 健；广州晶诚 敖峰；广州贤能 谭文；臻远基金 吴晗睿； 戴维斯双击投资 林杨波。 个人投资者 陈富康、廖林波、赵树忠、宋大亮、钟冰林。 时间 2023 年 5 月 17 日 15:00-17:30 地点 公司展厅及会议室 董事、副总经理、财务总监：骆雅红 上 市 公 司 接 待人员 董事、董事会秘书：龙小燕 一、公司董事会秘书简单介绍公司基本情况 投 资 者 关 系 活 动 主 ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2023004 ☐特定对象调研 ☐分析师会议 ☐媒体采访 投 资 者 关 系 活动类别 ☑业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐一对一沟通 ☐其他： 参 与 单 位 名 称 及 人 员 姓 名 线上参与公司 2022 年度网上业绩说明会的投资者 时间 2023 年 5 月 5 日 15:00-16:00 地点 价值在线（www.ir-online.cn） 董事长、总经理 袁玉宇 董事、副总经理、财务总监 骆雅红 上 市 公 司 接 待人员 董事、董事会秘书 龙小燕 副总经理 王建华 独立董事 颜光美 1.请问公司可有与云南白药合作开发可吸收止血绷带、可吸收创 口贴的计划？博纳力可吸收骨固定系统可否用在普通骨折外伤手术 中？避免两次手术拆除骨固定系统，我可是深受其害！公司可吸收口 投 资 者 关 系 活 动 主 要 内 容介绍 腔修复膜临床试验己进行到什么阶段？公司在研和准备开发的项目有 哪些？我建议公司十年内不要送红股、不要转赠股，终身不要配合资 本炒作股价。每年将盈利的百分之三十做现金分红 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥44,485,769.60, representing a 19.35% increase compared to ¥37,272,422.06 in the same period last year[6]. - Net profit attributable to shareholders for Q1 2023 was ¥7,816,548.85, up 9.19% from ¥7,165,807.56 in Q1 2022[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,454,127.50, a significant increase of 49.78% from ¥4,309,093.61 in the previous year[6]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.12, reflecting a 9.09% increase from ¥0.11 in the same quarter last year[6]. - The total operating revenue for the first quarter was CNY 44,485,769.60, an increase of 19.5% compared to CNY 37,272,422.06 in the previous period[28]. - The net profit for the first quarter reached CNY 7,816,548.85, representing a 9.3% increase from CNY 7,149,462.11 in the same period last year[29]. Cash Flow and Liquidity - The net cash flow from operating activities reached ¥19,434,599.35, a remarkable increase of 925.83% compared to a negative cash flow of ¥2,353,328.55 in Q1 2022[6]. - Operating cash flow net amount reached ¥19,434,599.35, a significant improvement from a negative ¥2,353,328.55 in the previous period, indicating a strong recovery in operational performance[33]. - Total cash inflow from operating activities was ¥66,508,610.90, compared to ¥45,011,097.35 in the prior period, reflecting a year-over-year increase of approximately 47.9%[33]. - Cash outflow from operating activities totaled ¥47,074,011.55, slightly decreased from ¥47,364,425.90, showing effective cost management[33]. - The cash and cash equivalents at the end of the period stood at ¥12,837,726.43, down from ¥8,156,838.16, indicating a decrease in liquidity[35]. - The total cash flow from operating, investing, and financing activities resulted in a net decrease of ¥31,925,042.71, compared to a decrease of ¥2,000,667.70 in the prior period, indicating overall cash management challenges[35]. Assets and Liabilities - Total assets at the end of Q1 2023 were ¥728,447,431.74, a decrease of 2.21% from ¥744,919,499.58 at the end of the previous year[6]. - The total liabilities decreased to CNY 118,048,593.35 from CNY 142,337,210.04 in the prior period[27]. - The company reported an increase in other receivables from ¥1,326,619.54 to ¥3,362,187.29 during the reporting period[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,460[16]. - The top two shareholders, Yuan Yuyu and Xu Tao, each hold 16.53% of the shares, totaling 10,922,547 shares[16]. - The top ten unrestricted shareholders hold a total of 11,362,136 shares, representing significant ownership concentration[16]. - The company has a pledge of 3,060,000 shares by shareholder Yuan Yuyu[16]. Government Subsidies and Non-Recurring Gains - The company received government subsidies amounting to ¥695,663.75 during the quarter, contributing to the increase in net profit[12]. - The company reported a total of ¥1,362,421.35 in non-recurring gains for the quarter, after accounting for tax effects[12]. - The significant increase in net cash flow was primarily due to revenue growth and receipt of government subsidies[15]. Research and Development - Research and development expenses were CNY 5,661,139.07, remaining stable compared to CNY 5,619,822.65 in the previous period[28]. - The company has successfully registered four new medical devices, including "hard meninges medical glue" and "titanium screws for craniofacial fixation," all classified as Class III medical devices[22]. Future Plans - The company plans to expand its market presence and invest in new technologies to drive future growth[29]. - The company has not disclosed any new strategies related to market expansion or mergers and acquisitions in the current report[21].

Financial Performance - The company's operating revenue for 2022 was ¥195,252,385.91, representing a 26.96% increase compared to ¥153,785,686.53 in 2021[22]. - The net profit attributable to shareholders for 2022 was ¥35,891,785.18, a decrease of 19.73% from ¥44,733,830.57 in 2021[22]. - Basic and diluted earnings per share for 2022 were both ¥0.54, down 31.65% from ¥0.79 in 2021[22]. - The company's total revenue for Q1 2022 was approximately ¥37.27 million, Q2 was ¥57.75 million, Q3 was ¥44.23 million, and Q4 was ¥56.00 million, indicating a strong performance in Q2[29]. - The net profit attributable to shareholders for Q1 2022 was ¥7.17 million, Q2 was ¥14.07 million, Q3 was ¥8.88 million, and Q4 was ¥5.77 million, showing fluctuations throughout the year[29]. - The company achieved operating revenue of 195.25 million yuan, a year-on-year increase of 26.96%[68]. - Net profit attributable to shareholders decreased by 19.73% to 35.89 million yuan, while net profit excluding non-recurring gains and losses increased by 2.67% to 23.94 million yuan[68]. - The company's revenue from implantable medical devices reached ¥189,452,993.26, accounting for 97.03% of total revenue, with a year-on-year growth of 28.35%[94]. - Revenue from overseas markets grew significantly by 62.51% to ¥35,976,735.68, representing 18.43% of total revenue[94]. Cash Flow and Investments - The net cash flow from operating activities decreased by 27.37% to ¥48,309,238.18 in 2022 from ¥66,510,692.29 in 2021[22]. - The company achieved a significant increase in cash and cash equivalents, totaling ¥34,605,263.28, a 2668.07% increase compared to a negative balance of ¥1,347,522.06 in the previous year[91]. - The total cash inflow from investment activities increased by 29.79% to ¥1,137,133,331.73 in 2022, while cash outflow decreased by 6.09% to ¥1,118,580,582.99[111]. - The net cash flow from investment activities turned positive at ¥18,552,748.74, a significant improvement of 105.89% from a negative ¥314,931,962.09 in the previous year[111]. - Investment income contributed ¥8,792,273.20, accounting for 22.00% of the total profit, primarily from returns on financial products[114]. - The total investment amount for 2022 was ¥227,169,646.05, representing a decrease of 39.84% from ¥375,571,502.73 in the previous year[120]. Research and Development - The company reported a significant focus on R&D in new medical technologies, particularly in the field of bio-materials and 3D printing applications for medical devices[14]. - The company’s R&D investment for 2022 was ¥40,572,232.74, a slight decrease of 2.61% from ¥41,658,606.43 in the previous year[91]. - The number of R&D personnel increased to 70 in 2022, representing an 18.64% growth from 59 in 2021[106]. - The company has developed multiple innovative products based on advanced manufacturing technologies, including bio-additive manufacturing and digital design[78]. - Clinical trials are ongoing for the absorbable multilayer fiber hemostatic product, which aims to enhance the company's offerings in the hemostatic product category[106]. Market Expansion and Product Development - The company is expanding its market presence with new product lines in cranio-maxillofacial repair systems, targeting both domestic and international markets[15]. - The company has successfully won bids for its "artificial dura mater patch" in four provinces, including Jiangsu, Shandong, Fujian, and Anhui, as part of a centralized procurement initiative[45]. - The craniofacial repair system, based on PEEK material, is one of the few domestic products designed for craniofacial defect repair, with significant market potential as it replaces traditional titanium materials[53]. - The company aims to strengthen its competitive advantage in the domestic market while enhancing its international market expansion efforts[74]. - The company plans to extend its technology platform applications to oral and other surgical fields, developing new product lines such as hemostatic agents and medical adhesives[130]. Governance and Management - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements[149]. - The company has established a performance evaluation and incentive mechanism for its senior management, ensuring transparency in the hiring process[150]. - The company maintains a complete and independent business operation, with no interference from controlling shareholders[152]. - The company has a robust financial independence, with a separate financial accounting system and no shared bank accounts with controlling shareholders[156]. - The company has a well-defined governance structure that promotes the protection of minority shareholders' rights[147]. Challenges and Risks - The company faces risks related to new product development and technological iteration, which could impact its market competitiveness if not addressed[138]. - Regulatory changes, such as national healthcare policies, pose risks that the company must navigate to maintain operational stability[139]. - Increased competition in the neurosurgical high-value medical consumables market necessitates continuous improvement in product development and marketing strategies[141]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 20% to 1.44 billion RMB, driven by new product launches and market expansion[171]. - The company plans to enhance its marketing capabilities by leveraging existing product advantages and participating in centralized procurement opportunities, aiming to increase brand influence and market penetration[132]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product portfolio and accelerate growth in regenerative medicine[171].